Merck (MRK) Impresses with New Cholesterol Drug in CORALreef Trial

Merck & Company, Inc. (NYSE:MRK) is one of the top 10 mega-cap stocks to buy according to hedge funds. On September 2, Merck & Company (NYSE:MRK) shared early results from a study called CORALreef Lipids. This study tested a new medicine named enlicitide decanoate.

Merck Impresses with New Cholesterol Drug in CORALreef Trial

Pixabay/Public Domain

It’s a pill you take once a day to help adults with high cholesterol. The study showed the medicine worked well; it lowered Low-Density Lipoprotein (LDL), also known as bad cholesterol, and other fats in the blood more than a fake pill called a placebo. They checked this after 24 weeks.

What’s also important is that the medicine seems safe. People taking it didn’t have more side effects than those taking the placebo. If the drug gets approved, it could be a lot easier for patients because it’s a pill, not a shot. While shots have been efficient, they have faced adoption challenges

Merck plans to show these results to health authorities worldwide and talk about them at future meetings. This study is part of a bigger effort called the CORALreef program. It tries to help many people who still can’t get their cholesterol under control, even with medicine.

While we acknowledge the potential of MRK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRK and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Tech Stocks to Buy According to Hedge Funds and 11 Best Stocks to Invest in for Long Term Growth 

Disclosure: None.